An interventional study of probiotic and placebo in Type2 Diabetes, Insulin Resistance and Probiotic, sponsored by Bogomolets National Medical University. Completed. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2019-12-17.
Sponsored by Bogomolets National Medical University · Not applicable, Interventional, and Treatment
Probiotics have beneficial effect on obesity related disorders in animal models. Despite a large number of animal data, randomized placebo-controlled trials (RCT) concluded that probiotics have a moderate effect on glycemic control-related parameters. However, effect of probiotics on insulin resistance are inconsistent. In this double-blind single center RCT, effect of alive multistrain probiotic vs. placebo on insulin resistance in type 2 diabetes patient will be assessed.
In this single-center double blind, placebo controlled, parallel group study, type 2 diabetes patients from the Kyiv City Clinical Endocrinology Center will be selected. They will be randomly assigned to receive multiprobiotic "Symbiter" or placebo for 8-weeks administered as a sachet formulation in double-blind treatment. Randomization will be done by the study statistician based on a computer-generated list. The groups will be homogeneous according to age, sex and diagnostic criteria. The assignment of groups will be blind to participants, research staff and outcome assessors moreover, to maintain blind parallel study the statistician was not aware of the allocation of participants to intervention.
The multiprobiotic "Symbiter" will be supplied by Scientific and Production Company "O.D. Prolisok". It contains of 14 alive probiotic strains of Lactobacillus + Lactococcus (6×1010 CFU/g), Bifidobacterium (1×1010/g), Propionibacterium (3×1010/g), Acetobacter (1×106/g) genera. Over 8 weeks of interventional period, the patient received 1 sachet (10 grams) of probiotic and placebo per day. All sachets were identical with similar organoleptic characteristics (e.g., taste and appearance).
The pre-randomization period designed to minimize the effects of dietary changes on metabolic markers. For this purpose, 2 weeks before the study start, after inform consent signed, patients will be instructed in one-on-one sessions with a dietitian to follow a therapeutic lifestyle-change diet as classified by the NCEP. In addition, participants will be instructed to continue with stable anti-hyperglycemic treatment and received standardized mild physical training for 1 hour per day.
Patients who underwent study will be instructed to take the trial medication as prescribed. Throughout the study, weekly phone follow-up visits will be provided for assessment of compliance, adherence to the protocol, as well as the recording of adverse events. The effectiveness of therapy will be compared and evaluated separately in the two groups.
Exclusion Criteria:
Over 8 weeks of interventional period, the patient received 1 sachet (10 grams) per day.
Dietary Supplement: probiotic
Over 8 weeks of interventional period, the patient received 1 sachet (10 grams) per day.
Dietary Supplement: placebo
The multiprobiotic "Symbiter" which contains of 14 alive probiotic strains of Lactobacillus + Lactococcus (6×1010 CFU/g), Bifidobacterium (1×1010/g), Propionibacterium (3×1010/g), Acetobacter (1×106/g) genera. Over 8 weeks of interventional period, the patient received 1 sachet (10 grams) of probiotic per day.
Over 8 weeks of interventional period, the patient received 1 sachet (10 grams) of gel per day
HOMA-IR
HOMA-IR was calculated according to the formula: fasting insulin (microU/L) x fasting glucose (nmol/L)/22.5
Time frame: 8 weeks compared to baseline
HbA1c
HbA1c in %
Time frame: 8 weeks compared to baseline
fasting plasma insulins (FPI)
FPI in microU/L
Time frame: 8 weeks compared to baseline
fasting plasma glucose (FPG)
FPG in mmol/L
Time frame: 8 weeks compared to baseline
weight
weight in kg
Time frame: 8 weeks compared to baseline
waist circumferences (WC)
WC in cm
Time frame: 8 weeks compared to baseline
body mass index (BMI)
weight and height will be combined to report BMI in kg/m\^2
Time frame: 8 weeks compared to baseline
cytokines levels
TNF-α, IL-1β, IL-6, IL-8, INF-γ
Time frame: 8 weeks compared to baseline
No study locations are listed for this record.
Plan to share: No
This study is completed, as verified in Dec 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Bogomolets National Medical University